Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $70,167.50 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,250 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $21.59, for a total value of $70,167.50. Following the completion of the sale, the chief financial officer now owns 13,000 shares of the company’s stock, valued at $280,670. This trade represents a 20.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.04, for a total value of $25,040.00.
• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.51, for a total value of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.15, for a total transaction of $74,202.50.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.89, for a total transaction of $130,672.50.

Enliven Therapeutics Stock Performance

NASDAQ:ELVN opened at $20.86 on Thursday. Enliven Therapeutics, Inc. has a fifty-two week low of $10.90 and a fifty-two week high of $30.03. The company has a 50 day moving average price of $23.27 and a 200 day moving average price of $24.33. The stock has a market capitalization of $1.02 billion, a P/E ratio of -10.98 and a beta of 1.04.

Wall Street Analyst Weigh In

Several research firms have recently commented on ELVN. Robert W. Baird lifted their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, November 15th. BTIG Research assumed coverage on Enliven Therapeutics in a report on Friday, December 13th. They set a “buy” rating and a $42.00 price target for the company. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $38.25.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. lifted its position in shares of Enliven Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock worth $232,000 after purchasing an additional 3,559 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Enliven Therapeutics during the 3rd quarter worth approximately $256,000. Verition Fund Management LLC purchased a new position in Enliven Therapeutics in the 3rd quarter valued at approximately $271,000. The Manufacturers Life Insurance Company acquired a new position in shares of Enliven Therapeutics in the second quarter worth $322,000. Finally, Quest Partners LLC increased its position in shares of Enliven Therapeutics by 1,226.4% during the third quarter. Quest Partners LLC now owns 21,117 shares of the company’s stock worth $539,000 after acquiring an additional 19,525 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.